| Population | Intervention | Comparators | Outcomes | Timing | Setting |
|---|---|---|---|---|---|
| Patient Characteristics Age Sex Race Ethnicity Performance status LDH CEA Clinical risk scores (e.g., Fong)95 Tumor Characteristics Location of tumor Size of lesions Number of lesions Tumor volume Portal vein obstruction Course of disease (stabilization, rapid progression) Other Treatments Number, dose, and duration for lines of prior therapy by drug Number, dose, and duration for lines of adjunctive therapy by drug Previous liver-directed therapy | Type of Local Hepatic Therapy Cryosurgical ablation RFA MWA TAE TACE HAI RE DEB 3D-CRT IMRT SBRT Characteristics of Local Hepatic Therapy Dose Duration Surgical site | Same as Intervention | Overall survival Quality of life Response (e.g., complete, partial, no response) Recovery time Length of stay Adverse effects (Short-term and long-term harms) Treatment holidays* | Ongoing | Hospital type Number of procedures by practitioner Type of practitioner Local hepatic therapy availability Inpatient or outpatient procedure |
3D-CRT = three-dimensional conformal radiation therapy; CEA = carcinoembryonic antigen; DEB = drug-eluting bead; HAI = hepatic artery infusion; IMRT = intensity-modulated radiation therapy; LDH = lactate dehydrogenase; RE = radioembolization; RFA = radiofrequency ablation; SBRT = stereotactic body radiation therapy; TACE = transarterial chemoembolization; TAE = transarterial embolization
Treatment holidays refer to time away from systemic chemotherapy and may vary based on the success of treatment with a local hepatic therapy.
From: Executive Summary
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.